IN2014MN01799A - - Google Patents

Info

Publication number
IN2014MN01799A
IN2014MN01799A IN1799MUN2014A IN2014MN01799A IN 2014MN01799 A IN2014MN01799 A IN 2014MN01799A IN 1799MUN2014 A IN1799MUN2014 A IN 1799MUN2014A IN 2014MN01799 A IN2014MN01799 A IN 2014MN01799A
Authority
IN
India
Prior art keywords
present
heat labile
labile toxin
strains
mutated
Prior art date
Application number
Inventor
Cerqueira Leite Luciana Cezar De
Nascimento Ivan Pereira
Original Assignee
Fundação Butantan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundação Butantan filed Critical Fundação Butantan
Publication of IN2014MN01799A publication Critical patent/IN2014MN01799A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to recombinant strains ofthat encode the mutated LT heat labile toxin or the A subunit of the mutated LT heat labile toxin. The present invention also relates to strains of that encode the LT heat labile toxin or the A subunit of the LT heat labile toxin of mutated in position 63. Specifically the present invention relates to strains of that encode the LT heat labile toxin or the A subunit of the LT heat labile toxin of mutated in position 63 from serine to lysine. The present invention also provides immunogenic compositions that comprise the strains of the present invention. The present invention further provides for the use of said strains and immunological compositions in the production of a vaccine for preventing tuberculosis and infections caused by Lastly the present invention relates to methods for preventing or treating tuberculosis in animals.
IN1799MUN2014 2012-02-17 2013-02-18 IN2014MN01799A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR102012003790-4A BR102012003790A2 (en) 2012-02-17 2012-02-17 RECOMBINANT MYCOBACTERIUM CEPA, IMMUNOGENIC COMPOSITION AND USE
PCT/BR2013/000049 WO2013120159A1 (en) 2012-02-17 2013-02-18 Recombinant strain of mycobacterium bovis bacillus calmette-guerin (bcg), immunogenic composition and use

Publications (1)

Publication Number Publication Date
IN2014MN01799A true IN2014MN01799A (en) 2015-07-03

Family

ID=48983477

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1799MUN2014 IN2014MN01799A (en) 2012-02-17 2013-02-18

Country Status (7)

Country Link
US (1) US9512186B2 (en)
EP (1) EP2816106B1 (en)
CN (1) CN104271733B (en)
BR (2) BR102012003790A2 (en)
IN (1) IN2014MN01799A (en)
WO (1) WO2013120159A1 (en)
ZA (1) ZA201406437B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201911636D0 (en) 2019-08-14 2019-09-25 Univ Surrey Vaccine
CN118715022A (en) * 2022-02-11 2024-09-27 布坦坦研究所 Compositions comprising recombinant mycobacterium strains, uses thereof and methods for preventing and/or treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504005A (en) 1987-03-02 1996-04-02 Albert Einstein College Of Medicine Of Yeshiva University Recombinant mycobacterial vaccine
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
GB0313242D0 (en) * 2003-06-09 2003-07-16 Imp College Innovations Ltd Pulmonary immunopathology
WO2009089535A2 (en) * 2008-01-11 2009-07-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Polypeptide vaccine and vaccination strategy against mycobacterium

Also Published As

Publication number Publication date
CN104271733A (en) 2015-01-07
ZA201406437B (en) 2016-03-30
US9512186B2 (en) 2016-12-06
EP2816106A1 (en) 2014-12-24
EP2816106A4 (en) 2015-07-29
BR112014020297A2 (en) 2017-06-20
BR112014020297B1 (en) 2022-01-25
BR102012003790A2 (en) 2014-04-22
WO2013120159A1 (en) 2013-08-22
CN104271733B (en) 2018-02-27
US20150152145A1 (en) 2015-06-04
EP2816106B1 (en) 2021-10-06

Similar Documents

Publication Publication Date Title
RU2017104529A (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND WAYS OF THEIR APPLICATION
MX2017001406A (en) Flagellin-based agents and uses including effective vaccination.
MX352324B (en) Multivalent synthetic nanocarrier vaccines.
MX340830B (en) Pneumococcal vaccine and uses thereof.
MX350013B (en) Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a.
MX2016003419A (en) Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods.
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2013054199A3 (en) Cmv antigens and uses thereof
EA201290876A1 (en) COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE
EA201691348A1 (en) ONE-FLAKE VACCINE COMPOSITIONS
EA201790239A1 (en) MOLECULE CARRIER FOR ANTIGENS
EA201290675A1 (en) VACCINE VECTORS AND METHODS OF STRENGTHENING IMMUNE RESPONSES
TN2016000435A1 (en) Novel macrocyclic compounds.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2015000287A (en) Vectors for transforming mycoplasma hyopneumoniae, transformed m. hyopneumoniae strains, and use thereof.
MY191217A (en) Group a streptococcus vaccine
PH12017500637A1 (en) Inhibitors of lysine gingipain
NZ702285A (en) Staphylococcal coagulase antigens and methods of their use
EA201892003A1 (en) TREATMENT OF ATOPIC DERMATITIS DOGS
IN2014MN01799A (en)
MX2018012270A (en) Novel pneumococcal vaccine formulations.
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
IN2014DN08610A (en)
BR112013023354A2 (en) equine rhinitis vaccine
EA201690378A1 (en) VACCINE COMPOSITIONS AGAINST NARCOTIC DEPENDENCE